Sign In
Buy CSTL
$20.39
+0.680 (+3.45%)
At Close: Jun 03, 2026
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates
06:21pm, Monday, 04'th Aug 2025
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.51 per share. This compares to earnings of $0.31 per share a y
Castle Biosciences Reports Second Quarter 2025 Results
04:05pm, Monday, 04'th Aug 2025
Delivered Q2 2025 revenue of $86 million Q 2 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 33% over Q 2 2024 Raising full-year 2025 revenue
New Strong Sell Stocks for August 1st
06:16am, Friday, 01'st Aug 2025
CRSP, CSTL and SIGI have been added to the Zacks Rank #5 (Strong Sell) List on August 1, 2025.
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
07:00am, Tuesday, 29'th Jul 2025
Castle Biosciences' executive management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference Aug. 12, 2025 at 12:30pm ET
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
11:06am, Monday, 28'th Jul 2025
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
07:00am, Friday, 25'th Jul 2025
FRIENDSWOOD, Texas, July 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its fo
FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma Test
07:00am, Wednesday, 23'rd Jul 2025
Castle announced that its DecisionDx®-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture
07:00am, Thursday, 17'th Jul 2025
FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
07:00am, Monday, 14'th Jul 2025
FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it wil
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 19'th Jun 2025
FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
04:30pm, Monday, 16'th Jun 2025
FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
07:00am, Wednesday, 11'th Jun 2025
FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek
Gold-level Stevie® Award recognizes Maetzold's transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NE
FRIENDSWOOD, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present novel research a
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
07:00am, Wednesday, 21'st May 2025
Castle's executive management will present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 am ET
